Sotera Health Co

Amendment No. 5 to the Revolving Credit Facility

On April 30, 2025, the Company and SHH entered into Amendment No. 5 to the Revolving Credit Facility, by and among the Company, SHH, certain subsidiaries of the Company, JPMorgan Chase Bank, N.A., as First Lien Administrative Agent and the lenders and issuing banks party thereto (together with the First Lien Administrative Agent, the “Lenders”). Among other changes, Amendment No. 5 provides (i) for an increase in the commitments under the existing Revolving Credit Facility in an aggregate principal amount of $176.2 million, (ii) that certain lenders providing revolving credit commitments shall also provide additional commitments for the issuance of letters of credit under the Revolving Credit Facility in an aggregate principal amount of $186.3 million and (iii) for the extension of the maturity date of the Revolving Credit Facility to April 30, 2030. Amendment No. 5 does not give effect to any other material changes to the terms and conditions of the Credit Agreement, including with respect to the representations and warranties, events of default and the affirmative or negative covenants. The Lenders party to Amendment No. 5 and their affiliates have provided investment banking, financial advisory and other services to the Company for customary fees and reimbursement of expenses, and those Lenders and affiliates may, from time to time, continue to do so. The foregoing description of certain provisions of the Amendment No. 5 and the underlying Credit Agreement does not purport to be complete and is qualified in its entirety by the full text of the Credit

Agreement and the Amendment, a copy of which is filed with this Quarterly Report on Form 10-Q as Exhibit 10.1 and incorporated herein by reference.

Rule 10b5-1 Trading Plans

During the three months ended March 31, 2025, none of the Company’s directors or officers (as defined in Rule 16a-1(f) under the Exchange Act)adopted orterminated any contract, instruction or written plan for the purchase or sale of Company securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement” (as that term is defined in Regulation S-K, Item 408).